logo-loader
Redx Pharma Plc

Redx Pharma poster hails the potential of new class of kidney and liver drug

Highly selective ROCK2 inhibitors are thought to suppress the release of pro-fibrotic factors from kidney mesangial cells

kidney
A new method of treating kidney fibrosis?

Richard Armer, chief scientific officer of Redx Pharma Plc (LON:REDX), believes the company’s new ROCK2 inhibitor drug has the potential to be a “best-in-class agent” for the treatment of fibrotic diseases of the kidney and liver.

His comments came at the conclusion of the American Society of Nephrology’s Kidney Week, in San Diego, California, at which Redx made a poster presentation hailing the potential of using the therapy to tackle chronic kidney disease.

Highly selective ROCK2 inhibitors are thought to suppress the release of pro-fibrotic factors from kidney mesangial cells.

Reduced damage

In an animal model of acute kidney injury, the Redx selective ROCK2 compound reduced damage and the expression of inflammatory and profibrotic genes in the kidney.

In addition, a rat study indicated that the Redx inhibitor avoided cardiovascular side-effects.

"We are pleased that our poster was presented at the high profile American Society of Nephrology Kidney Week,” said Armer.

“We believe our highly selective ROCK2 inhibitors have the potential to be best-in-class agents for the treatment of fibrotic diseases of the kidney such as diabetic nephropathy and of the liver such as non-alcoholic steatohepatitis.

“This is the first publication of our ROCK2 project data and we are delighted that the high quality of our research has been recognised by the ASN."

Quick facts: Redx Pharma Plc

Price: £0.10

Market: AIM
Market Cap: £12.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's Lisa Anson discusses potential US$203mln cancer deal

Redx Pharma PLC's (LON:REDX) Lisa Anson speaks to Proactive London's Andrew Scott after announcing they've sold one of their cancer research programmes for up to US$203mln. The agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) has a tiered payment structure and will see Redx receive a...

on 10/7/19

2 min read